Yonhap Infomax NewsJun 4, 2025
Merus shares hit record highs after Phase 2 data showed strong survival rates for its head and neck cancer therapy, fueling Wall Street optimism and positive analyst outlooks.
#YonhapInfomax #Merus #Keytruda #Phase2Data #SurvivalRate #SharePrice #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=66099
Merus Gains Wall Street Optimism on Head and Neck Cancer Drug Prospects

Merus shares hit record highs after Phase 2 data showed strong survival rates for its head and neck cancer therapy, fueling Wall Street optimism and positive analyst outlooks.

Yonhap Infomax